Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
48 hedge funds and large institutions have $4.66M invested in Oncternal Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 4 reducing their positions, and 25 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 4
13% less funds holding
Funds holding: 55 → 48 (-7)
17.94% less ownership
Funds ownership: 30.29% → 12.34% (-18%)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
59% less call options, than puts
Call options by funds: $540K | Put options by funds: $1.32M
96% less capital invested
Capital invested by funds: $104M → $4.66M (-$99.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$4.7M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$4.47M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$3.51M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.27M |
| 5 |
Millennium Management
New York
|
+$3.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$23M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$20.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$13M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.07M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$5.91M |
ONCT Hedge Fund Activity: Q3 2018 in Review
48 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2018, worth a combined $4.66M — down 96% from $104M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ONCT and 18 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 16 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $4.7M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $23M sold.
- 48 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2018, down from 55 in Q2 2018.
- Funds reported $4.66M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2018, down 96% quarter-over-quarter.
- 18 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2018 and 25 closed out, a net change of -7 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2018 was Bridgeway Capital Management, an estimated $4.7M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2018 was Perceptive Advisors, an estimated $23M sold.
Based on aggregated 13F filings for Q3 2018.